UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia

European psychiatry, 2021-04, Vol.64 (S1), p.S162-S162

2021

Volltextzugriff (PDF)

How Loading Dose Strategies for Depot Paliperidone Can Go Wrong

Journal of psychiatric practice, 2022-03, Vol.28 (2), p.130-137

Preskorn, Sheldon H

2022

Volltextzugriff (PDF)

Eight Clinical Cases and the Lessons They Taught

Journal of psychiatric practice, 2023-09, Vol.29 (5), p.373-377

Preskorn, Sheldon H.

2023

Volltextzugriff (PDF)

Nicolau syndrome associated with fluphenazine depot: A case report

SAGE open medical case reports, 2023-01, Vol.11, p.2050313X231180747

2023

Volltextzugriff (PDF)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder

Noro-Psikiyatri Arsivi, 2021-10, Vol.58 (S1), p.47-52

2021

Volltextzugriff (PDF)

Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada

BMC psychiatry, 2013-05, Vol.13 (1), p.155-155, Article 155

2013

Volltextzugriff (PDF)

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

Psychiatry and clinical psychopharmacology, 2018-07, Vol.28 (3), p.285-290

2018

Volltextzugriff (PDF)

The successful concurrent use of two long-acting depot antipsychotics in a patient with treatment-resistant schizophrenia and history of serious violence: a case report

Australasian psychiatry : bulletin of the Royal Australian and New Zealand College of Psychiatrists, 2017-04, Vol.25 (2), p.181-184

2017

Volltextzugriff (PDF)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

ClinicoEconomics and outcomes research, 2011-01, Vol.3 (default), p.9-14

2011

Volltextzugriff (PDF)

Guidelines for depot antipsychotic treatment in schizophrenia

European neuropsychopharmacology, 1998-02, Vol.8 (1), p.55-66

1998

Volltextzugriff (PDF)

Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability

Therapeutic advances in psychopharmacology, 2016-06, Vol.6 (3), p.162-171

2016

Volltextzugriff (PDF)

Medication adherence and the use of long-acting antipsychotics in bipolar disorder

Journal of psychiatric practice, 2007-03, Vol.13 (2), p.79-85

El-Mallakh, Rif S

2007

Volltextzugriff (PDF)

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

European Neuropsychopharmacology, 2004-03, Vol.14 (2), p.87-92

2004

Volltextzugriff (PDF)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

Patient preference and adherence, 2010-09, Vol.4 (default), p.325-334

2010

Volltextzugriff (PDF)

Perception of depot antipsychotics by mental health professionals

Journal of psychiatric practice, 2003-05, Vol.9 (3), p.252-260

2003

Volltextzugriff (PDF)

Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong

International journal of psychiatry in clinical practice, 2010, Vol.14 (1), p.23-32

2010

Volltextzugriff (PDF)

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Patient preference and adherence, 2010-09, Vol.4 (default), p.301-311

2010

Volltextzugriff (PDF)

Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral forms of the atypical and conventional antipsychotics marketed in Spain for treating patients with schizophrenia

Revista de psiquiatria y salud mental (English ed.), 2009, Vol.2 (1), p.5-28

2009

Volltextzugriff (PDF)

Comparación de la eficacia de las formas farmacéuticas de liberación retardada (depot) y las orales de los antipsicóticos típicos y atípicos comercializados en España para pacientes diagnosticados de esquizofrenia

Revista de psiquiatría y salud mental, 2009-03, Vol.2 (1), p.5-28

2009

Volltextzugriff (PDF)

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile

Neuropsychiatric disease and treatment, 2021-07, Vol.17, p.1917-1926

2021

Volltextzugriff (PDF)

Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials

Schizophrenia research, 2011-04, Vol.127 (1), p.83-92

2011

Volltextzugriff (PDF)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

BMC psychiatry, 2013-10, Vol.13 (1), p.261-261, Article 261

2013

Volltextzugriff (PDF)

Case series profile of olanzapine post‐injection delirium/sedation syndrome

British journal of clinical pharmacology, 2023-02, Vol.89 (2), p.903-907

2023

Volltextzugriff (PDF)

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia

The mental health clinician, 2021-09, Vol.11 (5), p.305-310

2021

Volltextzugriff (PDF)

Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study

Current medical research and opinion, 2024-05, Vol.40 (5), p.855-861

2024

Volltextzugriff (PDF)

1 – 25 von 261

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(243)
Mit Volltextzugriff
(190)

Publikationsform

Artikel
(257)
Buchkapitel
(4)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(201)
Science & Technology
(201)
Humans
(170)
Psychiatry
(157)
Schizophrenia
(157)
Antipsychotic Agents - Administration & Dosage
(121)
Schizophrenia - Drug Therapy
(116)
Depot
(100)
Male
(96)
Antipsychotic Agents - Therapeutic Use
(95)
Antipsychotics
(95)
Female
(94)
Adult
(89)
Delayed-Action Preparations
(89)
Pharmacology & Pharmacy
(87)
Middle Aged
(80)
Biological And Medical Sciences
(59)
Medical Sciences
(59)
Pharmacology. Drug Treatments
(58)
Antipsychotic Agents - Adverse Effects
(56)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Preliminary results of a network meta-analysis on the efficacy of long-acting injectable antipsychotics in schizophrenia

How Loading Dose Strategies for Depot Paliperidone Can Go Wrong

Eight Clinical Cases and the Lessons They Taught

Nicolau syndrome associated with fluphenazine depot: A case report

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder

Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada

A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

The successful concurrent use of two long-acting depot antipsychotics in a patient with treatment-resistant schizophrenia and history of serious violence: a case report

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia

Guidelines for depot antipsychotic treatment in schizophrenia

Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability

Medication adherence and the use of long-acting antipsychotics in bipolar disorder

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

Perception of depot antipsychotics by mental health professionals

Perceptions on efficacy and side effects of conventional depot antipsychotics (CDA) and atypical depot antipsychotics (ADA): Psychiatrists versus patients in Hong Kong

Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence

Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral forms of the atypical and conventional antipsychotics marketed in Spain for treating patients with schizophrenia

Comparación de la eficacia de las formas farmacéuticas de liberación retardada (depot) y las orales de los antipsicóticos típicos y atípicos comercializados en España para pacientes diagnosticados de esquizofrenia

Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile

Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

Case series profile of olanzapine post‐injection delirium/sedation syndrome

The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia

Real-world effectiveness of long-acting injectable vs. oral antipsychotics in patients with bipolar I disorder: a 1-year retrospective observational study

Suchergebnisse filtern